Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation

British Journal of Ophthalmology

Volumn 98, Issue 2, 2014, Pages 200-206

  Kellner, Simone ^a,b   Weinitz, Silke ^a,b   Farmand, Ghazaleh ^a   Kellner, Ulrich ^a,b  

^a MVZ ADTC Siegburg GmbH   (Germany)

^b RetinaScience   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE IMAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG SAFETY; DRUG WITHDRAWAL; EPIRETINAL MEMBRANE; FEMALE; HUMAN; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA FOVEA; RETINA MACULA CYSTOID EDEMA; RETINAL THICKNESS; RETINOPATHY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT DURATION; VISUAL ACUITY;

DEGENERATION; DRUGS; IMAGING; MACULA;

AGED; ANTIRHEUMATIC AGENTS; CHLOROQUINE; DISEASE PROGRESSION; ELECTRORETINOGRAPHY; EPIRETINAL MEMBRANE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; PROGNOSIS; RETINA; RETINAL DISEASES; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; WITHHOLDING TREATMENT;

EID: 84892576797     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303897     Document Type: Article

References (25)

1. Carr RE, Henkind P, Rothfield N, et al. Ocular toxicity of antimalarial drugs. Long-term follow-up. Am J Ophthalmol 1968; 66: 738-44.
2. Brinkley JR Jr, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol 1979; 88: 1-11. (Pubitemid 9187758)
3. Easterbrook M. Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 1992; 27: 237-9.
4. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/ hydroxychloroquine. Invest Ophthalmol Vis Sci 2006; 47: 3531-8. (Pubitemid 351639720)
5. Marmor MF, Kellner U, Lai TYY, et al. for the American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy 2010. Ophthalmology 2011; 118: 415-22.
6. Salu P, Uvijls A, van den Brande P, et al. Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with years follow-up. Doc Ophthalmol 2010; 120: 251-64.
7. Michaelides M, Stover NB, Francis PJ, et al. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol 2011; 129: 30-9.
8. Kazi MS, Saurabh K, Rishi P, et al. Delayed onset chloroquine retinopathy presenting years after long-term usage of chloroquine. Middle East Afr J Ophthalmol 2013; 20: 89-91.
9. Hood DC, Bach M, Brigell M, et al. ISCEV Standard for clinical multifocal electroretinography (2011 edition). Doc Ophthalmol 2012; 124: 1-13.
10. Kellner U, Kellner S, Weinitz S. Chloroquine retinopathy: lipofuscin- and melanin-related fundus autofluorescence, optical coherence tomography and multifocal electroretinography. Doc Ophthalmol 2008; 116: 119-27.
11. Kellner S, Kellner U, Weinitz S. Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence. Br J Ophthalmol 2009; 93: 1444-7.
12. Turgut B, Turkcuoglu P, Serdar Koca S, et al. Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography. Clin Rheumatol 2009; 28: 607-9.
13. Lee WJ, Ko MK, Lee BR. Hydroxychloroquine retinopathy combined with retinal pigment epithelium detachment. Cutan Ocul Toxicol 2012; 31: 144-7.
14. Kellner U, Kellner S, Weber BH, et al. Lipofuscin- and melanin-related fundus autofluorescence visualize different retinal pigment epithelial alterations in patients with retinitis pigmentosa. Eye (Lond) 2009; 23: 1349-59.
15. Sachs DD, Hoban MJ, Engleman EP. Chorioretinopathy induced by chronic administration of chloroquine phosphate. Arthritis Rheum 1962; b: 318-19.
16. Reed H, Karlinsky K. Delayed onset chloroquine retinopathy. Can Med Assoc J 1967; 97: 1408-11.
17. Ehrenfeld M, Nesher R, Merin S. Delayed onset chloroquine retinopathy. Br J Ophthalmol 1968; 70: 281-3.
18. Martin LJ, Bergen RL, Dobrow HR. Delayed onset chloroquine retinopathy: case report. Ann Ophthalmol 1978; 10: 723-6. (Pubitemid 8376526)
19. Wei LC, Chen SN, Ho CL, et al. Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report. Chang Gung Med J 2001; 24: 329-34.
20. Marmor MF, Fulton AB, Holder GE, et al. Standard for clinical electroretinography (2008 update). Doc Ophthalmol 2009; 118: 69-77.
21. Marks JS. Chloroquine retinopathy: Is there a safe daily dose? Annals Rheumatic Dis 1982; 41: 52-8. (Pubitemid 12136652)
22. Scholl S, Augustin A, Loewenstein A, et al. General pathophysiology of macular edema. Eur J Ophthalmol 2011; 21(Suppl 6): S10-19.
23. Snead DR, James S, Snead MP. Pathological changes in the vitreoretinal junction 1: epiretinal membrane formation. Eye (Lond) 2008; 22: 1310-17.
24. Harada C, Mitamura Y, Harada T. The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells. Prog Retin Eye Res 2006; 25: 149-64. (Pubitemid 43227842)
25. McCarthy DJ, Mukeh BN, Chikani V, et al. Prevalence and associations of epiretinal membranes in the visual impairment project. Am J Ophthalmol 2005; 140: 288-94.